Biopharma Informatic Incorporated — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$8,780	2
2024	Research	$11,198	2
2023	Research	$27,700	2
2022	Research	$28,788	1
2021	Research	$1,125	2
2020	Research	$18,949	2

Breakdown

Who paid Research payments · program years 2020–2025

E.R. Squibb & Sons, L.L.C. $88,351 6 payments
Amgen Inc. $6,565 2 payments
Celgene Corporation $1,623 3 payments

Studies the money was for Research payments · program years 2020–2025

A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Bms-986036 (Peg-Fgf21) in Adults With Nonalcoholic Steatohepatitis (Nash) and Stage 3 Liver Fibrosis $28,788 1 payment
A Phase 4, Global, Prospective, Open label Study of Ozanimod to Explore the Safety, Efficacy, Quality of Life, and Biomarker Response in Participants with Moderate to Severe Ulcerative Colitis in Clinical Practice $21,850 2 payments
A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Assess the Efficacy and Safety of Branebrutinib Treatment in Subjects With Active Systemic Lupus Erythematosus or Primary Sjgren's Syndrome, or Branebrutinib Treatment Followed by Open- $18,450 1 payment
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive HCM) $12,700 1 payment
An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice $6,563 1 payment
P2 UC $4,348 1 payment
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-2) $2,217 1 payment
A Phase 3, Multicenter, Randomized, Double-blind, $1,000 1 payment
PhIII Yellowstone Induction Study # 1 OZANIMOD in Moderate to Severe CD (RPC01-3201) (BMS Study Number: IM047-P14) $499 1 payment
Induction Study #1 - A Phase 3, Multicenter, Rando $125 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.